Last reviewed · How we verify
AmnioExCel dressing and compression therapy
AmnioExCel is an amniotic membrane-derived wound dressing that promotes tissue healing and reduces inflammation when combined with compression therapy for chronic wounds.
AmnioExCel is an amniotic membrane-derived wound dressing that promotes tissue healing and reduces inflammation when combined with compression therapy for chronic wounds. Used for Chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers), Acute and traumatic wounds.
At a glance
| Generic name | AmnioExCel dressing and compression therapy |
|---|---|
| Sponsor | Prisma Health-Upstate |
| Drug class | Biologic wound dressing |
| Modality | Biologic |
| Therapeutic area | Wound Care / Dermatology |
| Phase | FDA-approved |
Mechanism of action
AmnioExCel contains bioactive proteins, growth factors, and extracellular matrix components derived from amniotic tissue that facilitate wound healing, angiogenesis, and tissue regeneration. When used with compression therapy, it creates an optimal microenvironment for wound closure while reducing edema and improving blood flow to promote faster epithelialization and tissue repair.
Approved indications
- Chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers)
- Acute and traumatic wounds
Common side effects
- Infection at wound site
- Allergic reaction
- Delayed wound healing
Key clinical trials
- Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations (PHASE4)
- AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: